Change in CGM measured glycemic variability (coefficient of variation)
Change in HbA1c
Change in albumin to creatinine ratio (ACR)
Change in blood pressure (systolic, diastolic, mean and pulse pressure)
Change in brachial arterial distensibility (Brach D), augmentation index by radial artery tonometry [pulse wave analysis [PWA]), pulse wave velocity (PWV)], and carotid atherosclerosis by carotid intima media thickness (cIMT)
Change in cardiac and aortic structure and function measured by cardiac magnetic resonance (CMR)
Change in ectopic fat volumes in the abdomen and around the heart
Change in estimated glomerular filtration rate (eGFR)
Change in insulin dose (total daily dose, units/kg of body weight)
Change in lipid parameters
Change in mean glucose
Change in patient reported quality of life
Change in weight
Differences in CGM metrics (mean glucose, TIR, TAR, TBR and CV) by daytime vs nighttime
Percent time spent in CGM-measured glucose >180 mg/dL and >250 mg/dL
Percent time spent in CGM-measured glucose range of 70-140 mg/dL (time in tight target range; TTIR)
Percentage of patients achieving HbA1c <7%
Percentage of patients achieving TIR >70%
Proportion of adults with T1D achieving composite outcome (CGM-measured time in range (TIR)>70% with time below range (TBR) of <4% and reduction in body weight by 5%) at 26 weeks in the semaglutide group compared to placebo group
Proportion of adults with T1D achieving composite outcome (CGM-measured time in range (TIR)>70% with time below range (TBR) of <5% and reduction in body weight by 5%) at 26 weeks in the semaglutide group compared to placebo group
Severe hypoglycemia and diabetic ketoacidosis episodes
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?